Login to Your Account

Lilly looks to Halozyme delivery technology in potential $825M dea

By Michael Fitzhugh
Staff Writer

Monday, December 21, 2015

Halozyme Therapeutics Inc. added Eli Lilly and Co. to the roster of companies angling to develop products incorporating its Enhanze delivery platform, a potential aid in the dispersion and absorption of its injectables.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription